

# Update on Canine Parvovirus: Molecular and Genomic Aspects, with Emphasis on Genetic Variants Affecting the Canine Host

Soulasack VANNAMAHAXAY<sup>1</sup> Phongsakorn CHUAMMITRI<sup>2,3</sup> 

- <sup>1</sup> Program in Veterinary Science, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, THAILAND  
<sup>2</sup> Veterinary Paraclinical Sciences Unit, Department of Veterinary Biosciences and Public Health, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, THAILAND  
<sup>3</sup> Excellent Center in Veterinary Biosciences (ECVB), Department of Veterinary Biosciences and Public Health, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, THAILAND

Article Code: KVFD-2017-17673 Received: 01.03.2017 Accepted: 17.04.2017 Published Online: 06.06.2017

## Citation of This Article

**Vannamahaxay S, Chuammitri P:** Update on canine Parvovirus: Molecular and genomic aspects, with emphasis on genetic variants affecting the canine host. *Kafkas Univ Vet Fak Derg*, 23 (5): 847-856, 2017. DOI: 10.9775/kvfd.2017.17673

## Abstract

Canine parvovirus (CPV), the etiology of hemorrhagic enteritis in dogs, was first isolated as CPV type 2 (CPV-2) almost 40 years ago, and was soon replaced by the emergence of new variant types. The major viral capsid proteins encoded by the VP2 gene are the sites where amino acids are often substituted, accounting for the unusual nature of this type of DNA virus. The alteration of specific residues has contributed to different antigenic variants which have affected the evolution of virus binding and host immunity to this virus. Sequence analysis of the VP2 gene and subsequent characterization have revealed three circulating CPV-2 strains, CPV-2a, CPV-2b, and CPV-2c, identified by mutations at amino acid residue 426. The latter strain displays increased pathogenicity in dogs and an extended host range. The present review article aimed at updating contemporary information on epidemiological studies and surveys from CPV field work. Moreover, we pointed out some sensitive and rapid diagnostic tools for detecting CPV in clinical samples, techniques which will be useful for health monitoring and management of CPV with currently available vaccines.

**Keywords:** *Canine Parvovirus, CPV type 2, Genetic Variation, VP2 Gene, Mutation, Dog*

## Köpek Parvovirusu Üzerine Bir Güncelleme: Köpek Konakçıya Etki Eden Genetik Varyasyonların Moleküler ve Genomik Özellikleri

### Özet

Köpeklerde hemorajik enteritin etiyolojik etkeni olan Canine parvovirus (CPV) neredeyse 40 yıl önce ilk olarak CPV tip 2 (CPV-2) olarak izole edildi ve hemen sonrasında ortaya çıkan yeni varyant tipler CPV tip 2'nin yerine geçti. VP2 geni tarafından kodlanan major viral kapsid proteinler aynı zamanda en sıklıkla amino asitlerin başka amino asitlerle değiştiği alanlar olup bu tip DNA virusların aykırı doğasının da sebebini oluşturmaktadır. Spesifik yapılarıdaki değişimler farklı antijenik varyantların oluşmasına katkıda bulunarak bu virüsün bağlanma ve virusa karşı konakçı bağışıklığının değişmesini etkilemiştir. VP2 geninin sekans analizi ve takibinde karakterizasyonu, 426. amino asitte mutasyon ile şekillenen CPV-2a, CPV-2b ve CPV-2c olmak üzere dolaşımda 3 farklı CPV-2 suşunun olduğunu göstermiştir. CPV-2c köpeklerde artmış patojenite ve daha geniş konakçı yelpazesi göstermektedir. Bu derlemede güncel epidemiyolojik çalışmalar ile CPV saha çalışmaları hakkındaki bilgilerin güncellenmesi amaçlanmıştır. Ayrıca, klinik örneklerde CPV'nin tanısında kullanılmak suretiyle sağlık taramasında faydalı olabilecek ve mevcut aşılarda CPV'nin kontrol altına alınmasında faydalı olabilecek bazı hassas ve hızlı tanı yöntemleri değerlendirilmiştir.

**Anahtar sözcükler:** *Canine Parvovirus, CPV tip 2, Genetik Varvasyon, VP2 Geni, Mutasyon, Köpek*

## INTRODUCTION

Canine parvovirus (CPV) is a contagious, life-threatening viral disease in young dogs, with a wide host range in many mammalian families: Mustelidae (ferrets, minks, and badgers), Canidae (dogs, foxes, and wolves), Procyonidae

(raccoons), and Felidae (cats, lions, tigers, and cheetahs) [1]. This viral disease is very common in unvaccinated dogs living in densely populated areas. The transmission of CPV is mediated by persons, animals, and fomites that come in contact with infected secretions or materials, such as feces, blood, food bowls, clothing, or bedding. The most



### İletişim (Correspondence)



+66 53 948046; Fax: +66 53 948065



phongsakorn.c@cmu.ac.th, phongsakorn@gmail.com

clinically significant forms induced by CPV are hemorrhagic enteritis, or bloody diarrhea. The general clinical signs may present as anorexia, depression, vomiting, fever, and mucoid or watery diarrhea. In severe cases, dehydration and hypovolemic shock may occur. The mortality rate in puppies can reach more than 70%, whereas the rate in the adults is less than 1% [2]. Canine parvovirus replication occurs in host cell nuclei and requires rapidly dividing cells of fetuses, newborns, lymphoid tissue, and intestinal epithelium of animals. The CPVs spread easily and are highly stable in the environment, able to survive in harsh conditions for about six weeks [1,3].

*Puppies without or inadequate titer of maternal-derived antibody (MDA) to this virus are prone to be infected* [4]. In any circumstances, healthy dogs or infected dogs with hemagglutination inhibition (HI) titer of 320 or higher are suggested to be protected from virus replication [4]. With sufficient protective immunity, the feces of dogs challenged with CPV-2 remained undetectable of CPV DNA by real-time PCR if they had the HI titer level of 320 of MDA [4]. In case of a low HI titer, such as 160 and lower, active CPV can be demonstrated by utilizing a reliable, sensitive method such as real-time PCR to detect the presence of the viral genome [5-7].

## CANINE PARVOVIRUS AND ITS GENOMIC ASPECTS

Canine parvovirus is a DNA virus and a member of the Parvoviridae family. This virus family consists of two subfamilies, *Parvovirinae* and *Densovirinae*. According to available information, *Parvovirinae* viruses are able to infect vertebrate hosts, while the latter subfamily can only infect insects. Currently, the *Parvovirinae* subfamily is comprised of eight genera, namely *Amdoparvovirus*, *Aveparvovirus*, *Bocaparvovirus*, *Copiparvovirus*, *Dependoparvovirus*, *Erythroparvovirus*, *Protoparvovirus*, and *Tetra parvovirus* [8]. The unique viruses in the genus *Parvovirus* are canine parvovirus (CPV) and feline panleukopenia virus (FPV), which are now well characterized [8].

Parvoviruses are non-enveloped viruses, single-stranded DNA approximately 25 nm in diameter. The parvovirus genome consists of approximately 5,323 nucleotides [9]. The full length of the viral genome contains two large open reading frames (ORFs). The first ORF is encoded for two nonstructural proteins (NS1 and NS2). The second ORF is built up of three structural proteins or capsid proteins (VP1, VP2, and VP3) through an alternative splicing of the same mRNAs [3]. The parvovirus capsid is icosahedral and consists mainly of 60 subunits of the polyproteins VP1 and VP2 [3,10]. VP3 is a product of VP2 from virus-host interactions when cleaved by proteolytic enzymes [9].

*The global distribution of contemporary CPV is thought to be divergent from canine minute virus (CnMV)* [9]. This virus,

formerly known as canine parvovirus type 1 (CPV-1), has caused neonatal death in puppies [8]. It has been documented that CPV-1 emerged from feline parvovirus (FPV) and has been circulating worldwide since the 1970s [11]. A few years later, the first CPV-2 isolates were discovered [12]. CPV-2 causes severe hemorrhagic gastroenteritis in dogs, as well as myocarditis [11].

The evolution of the original CPV-2 was established in the mid-1980s [6]. Since that time, the original CPV-2 (simply called "CPV-2") has been completely replaced by alternative variants, the first two of which are known as CPV-2a and CPV-2b [6]. *This phenomenon suggests that CPV-2 has evolved a highly fit conformation* [13]. In 2000, a new CPV subtype, CPV-2c, was detected, and it is now confirmed to be co-circulating with the other presenting subtypes [6].

At present, the antigens or subtypes of CPVs can be systematically identified using certain amino acid residues positioned within the VP2 protein. The antigenicity of CPVs, which determines the host range, is associated with VP2 capsid proteins. There is an antigenicity difference frequency of CPV-2a/2b detection [5,14,15]. The introduction of the CPV-2c strain was reported in 2001 [16]. CPV-2c is more widespread in South America [17,18], with the exception of Brazil where all circulating strains were characterized as CPV-2a or -2b [19,20]; few CPV-2c strains have been detected in India [21,22].

The VP2 protein is a favored location for mutations. *This protein accounts for interactions with host transferrin receptor (TfR). Once alterations become permanent, the affinity to canine TfR could be significantly enhanced* [11,23]. The favorability of mitotically active tissues, such as actively dividing intestinal cells and myocardiocytes in canine puppies, leads to the pathogenesis of CPV infection because the transferrin receptors are highly expressed in those cells [24].

## CANINE TRANSFERRIN RECEPTOR (TfR), AND CPV RECEPTOR RECOGNITION

The adaptation of receptor binding to canine transferrin receptor (TfR) type-1 has resulted in the extension of the host range of this virus, which for the newer antigenic types now includes both dogs and cats [11,25,26]. *Canine parvovirus has evolved its ability to bind the TfR type-1 by naturally occurring mutation of capsid protein (VP2) which conferred small local changes* [27]. The binding of the canine TfR plays a critical role in the canine parvoviral infection [28]. The TfR-capsid interaction depicted asymmetrical docking conformation [29,30]. *It is postulated in vitro study that binding of viral capsid to canine TfR, required only a small number of TfR (one to five TfRs per capsid) in initiation of infection* [29-31].

The alteration of hydrogen bonds and amino acid sub-

stitution at position 300 of VP2 are likely to cause a great susceptibility of the host receptor in binding of the viral particles [27,32]. Adjacent to residue 300, replacement of Gly299 (G299) increased hydrogen bonds with aiding in the flexibility of capsid surface loop [27]. The single point mutation between two AA residues is unlikely to cause the major change in protein structure, but this phenomenon can enhance the thermodynamic properties or entropy of surrounding AAs [27,33] and further influence the interaction between viruses and TfR.

The CPV-2a, which has descended from CPV-2, has a broad host range of both domestic and wild carnivores [27]. The certain substitution of AAs on the exterior surface of VP2 (G299K/A300K) has demonstrated the efficient binding to the receptor and eventually allowed virus entry into both feline and canine cells [29]. Within the virus-binding region of canine TfR and closely related canids (e.g. coyotes, and gray wolves), the glycan molecules at glycosylation site has been discovered to influence the binding of the virus thus promote the infection of canine cells [29,34,35]. The presence of glycosylation site prevents binding and infection of FPV-like virus in dogs, but this event was later overcome by antigenic variants of CPV-2 [32,36-38], suggesting that a specific Gly300 residue has some potential to bind efficiently to canine TfR [32]. The changes of specific AAs of three-fold spike of new antigenic CPV-2a, -2b and -2c (e.g. AA # 87, 101, 297, 300, and 305) resulted in the cross-species viral transfer and adaptation to new hosts [28], while the differences of AA residue 426 dictate antigenic variants of CPV-2 [28]. The mutation at AA residue 300 (e.g. Trp300), and its neighboring AA residues 299 and 301, has rendered CPV non-infectious for a dog with an exception for other animal species (e.g. cat and fox) [32]. *It is important to note that AA position at 300 of VP2 proteins may be considered as a key determinant of CPV host tropism through TfR binding [6] and even more about the pandemic emergence of CPV [24,27,32,39,40].*

The study of glycosylation found at TfRs of some carnivorous animals demonstrated the variation in patterns in which highly suggesting that the presence of glycan of domestic dog TfR forces the susceptibility to CPV [32]. The binding of AA residues near the 3-fold spike of VP2, especially residues 299 to 301, with TfR required the change of residue 300 (A300G) of virus to gain access to dog host, whereas there were some evident dictated that the mutation of residue 299 (G299E) or residue 300 (A300D) causing reduced binding and infectivity of canine TfR [24,29,31,32,38,40].

## AMINO ACID CHANGES AND CPV TYPE 2 VARIANTS

The emergence of new CPV-2 subtypes, specifically CPV-2c, has drawn attention to how well they fit to the canine host. *CPV-2c is thought to have a less severe clinical course and a lower mortality rate, as observed in dogs infected with the Glu-426 mutant (currently known as CPV-2c) compared with outbreaks caused by CPV-2a and CPV-2b [16,41].* The alterations of amino acids (AA) in the VP2 protein at specific residues - asparagine to glutamic acid (N426E) and aspartic acid to glutamic acid (D426E) - as determined by the antigenicity of antibodies has resulted in different antigenic detection of monoclonal antibodies, as shown in many studies [6,11,42] (Fig. 1). From the perspective of humoral immunity, the monoclonal antibodies (mAbs) A4E3 and C1D1 could recognize this novel antigenic determinant occurring within the major antigenic sites of VP2 in the CPV-2 virus [43]. The other site in VP2 where alterations are often detected is the amino acid residue at the 440 position. The threonine to alanine mutation (T440A) is of interest since it is located in close proximity to the Glu426 residue in the major antigenic site, or epitope A, found on the three-fold spike of the CPV capsid protein [6].

Indeed, progressive changes inside the capsid protein (particularly VP2) have been occurring throughout the past three decades, and these changes are continuing; however, the transformation seems rather small [11]. Changes at the 426 amino acid residue may account for the spread of all CPV-2 subtypes. *The new mutant VP2 structure may improve the biological properties of the virus, contributing to canine host adaptation, stabilization of the VP2 capsid structure, and enhanced antigenic escape from monoclonal antibodies [44].*

Many studies have identified the changes in amino acid residues located within the full-length gene encoding the main capsid protein VP2. Here, we list some of these changes in amino acids (Table 1). It is currently unknown whether the various new mutants, such as S297A, D426E, or T265P, are also associated with altered receptor binding [11]. Analysis of the VP2 protein has shown that all CPV-2c strains and sequenced CPV-2a/2b strains retain the AA changes of the variants with respect to the original CPV-2 (M87L, I101T, A300G, D305Y, N375D) and display the S297A mutation typical of the recent CPV-2a/2b isolates [45]. The most relevant change was at T440A, which was encountered in one United States. type 2c strain (110/07-27), but also in two type 2a Italian strains (333/05 and

**Table 1.** Frequent amino acid mutation sites found in full-length VP2 genes of canine parvovirus [16,45-48] compared with a reference strain (accession number M38245)

87	101	267	297	300	305	324	375	389	418	426	440	555
M87L	I101T	F267Y	S297A	A300G	D305Y	Y324I	N375D	T389N	I418T	N426D N426E	T440A	V555I

80/08)<sup>[45]</sup>. This change was also present in some reference isolates, CPV-2a (northern India) and K022 (South Korea) and CPV-2b LCPV-V204 (Vietnam)<sup>[45]</sup>. In contrast, strain CPV-2b 311/04 (Italy) displayed a different change at the same position (T440N) and a further change in a nearby residue (D434V)<sup>[45]</sup>.

The GH loop, situated between the  $\beta$ G and  $\beta$ H strands of the capsid surface (VP2) of the parvovirus, is formed by residues 267 to 498. This region contains sites with the most variability, influenced by its presentation on the capsid surface<sup>[10,45]</sup>. Aside from amino acids 297 and 440, changes detected in the GH loop of the VP2 protein of CPV-2c were R274K, F420L, N421Y, and V463I, of which the change at position 463 has been identified in a Korean CPV-2a isolate<sup>[49]</sup>.

## PREVALENCE OF CANINE PARVOVIRUS TYPE 2 VARIANTS


A new antigenic variation, carrying the AA substitution Asp426Glu (D426E) in the major antigenic site of the viral capsid protein VP2, was first reported in 2001 by a group of Italian virologists<sup>[16,41]</sup>. This newest variant, designated CPV-2c, has already been detected in other European countries, as well as in Asia, Africa, and the Americas. Five AA changes are present in the VP2 capsid protein, while the antigenic differences observed in CPV-2b are the consequence of only one AA substitution (Asn426Asp; N426D) located in the major antigenic site of the capsid (epitope A) (Fig. 1). CPV-2, on the other hand, replicates poorly in feline cells *in vitro*; however, this finding was not in accordance with the results of an *in vivo* study of live cats<sup>[11]</sup>. CPV-2c displays

a low genetic variability and shared amino acid changes already detected in recent CPV-2a/2b isolates<sup>[45]</sup>.


The prevalence of CPV-2 subtypes has been intensively studied at only a few laboratories. The majority of reports were derived mainly from countries in Europe, America, and Asia, where there are suspected endemic areas. We have collected information from a public dataset, which is summarized in a phylogenetic tree (Fig. 2). The phylogenetic clusters accounting for the geographical distribution were created using selected full-length amino acid sequences of the VP2 capsid protein (full 584 AAs) from various types of viruses (FPV, CPV-2, CPV-2a, CPV-2b, and CPV-2c) with the corresponding GenBank accessions (Fig. 2).

CPV-2c has been identified by sequencing at the major antigenic variation within the VP2 capsid. CPV-2c is the dominant and most prevalent type of CPV-2 that has been spreading in Argentina<sup>[44,50,51]</sup>, Ecuador<sup>[52]</sup>, Uruguay<sup>[53]</sup>, and Rio de Janeiro, Brazil<sup>[54]</sup>. In Colombia, the presence of the antigenic variants CPV-2a/2b with a possible new CPV-2a are currently circulating<sup>[55]</sup>.

In the United States and Mexico, CPV-2 types have been documented as CPV-2, CPV-2b, as well as CPV-2c<sup>[1,6,53-55]</sup>. In Asia, CPV-2a and 2b are currently predominant in Japan<sup>[56,57]</sup>, Taiwan<sup>[58,59]</sup>, and South Korea<sup>[60,61]</sup>. In Vietnam, CPV-2c<sup>[42]</sup> is often used as a reference strain for the naturally occurring Vietnamese HNI-4-1 prototype<sup>[45]</sup>. In Thailand, dog populations are often crowded into urban and metropolitan areas such as Bangkok and Chiang Mai. It was previously reported that CPV-2, CPV-2a and CPV-2b were the pre-dominant types found in Bangkok and the vicinity<sup>[26]</sup>.



**Fig 1.** Amino acid variations in capsid protein (VP2) of canine parvoviruses (CPV). (A) Surface representation structures of VP2, with residue 426 highlighted in red and nearby amino acids shown in lime green. Enlarged views of the 426 position are provided. (B) Graphical representation of VP2 capsid protein depicts the  $\beta$  strands of the eight-stranded antiparallel  $\beta$  barrel (red),  $\alpha$  helices (blue), and loops (green) in the structure. The N-terminal is labeled 'G37' and the C-terminal end is labeled 'Y584'. Magnified views of the original residue 426 from CPV-2a (N426), or substituted residues in CPV-2b (D426), and CPV-2c (E426), which account for CPV-2 variants, are shown with stick configurations. This graphic is derived from PDB accession number 2CAS



More recently, we discovered that mixed types of CPV-2 - CPV-2a, CPV-2b, and CPV-2c - circulate in combination and cause mucoid or bloody diarrhea in dogs residing in the Chiang Mai municipality (unpublished data). There has also been a recent CPV-2c epidemic in Vientiane, Laos [64] and Taiwan [65]. In China's capital city, Beijing, CPV-2a and 2b remain the dominant types of this virus [47,66-68], but more recently, the presence of CPV-2c has been confirmed in China [9,69-71]. In India and Iran, the dominant types in recent outbreaks were CPV-2a and -2b [21,72,73]. In 2016, CPV-2c was detected in northern and central India [74,75] and Iran [73].

In European countries, the co-circulation of CPV-2a, -2b, and -2c has been reported [76,77]. CPV-2c, causing gastroenteritis in dogs, has been detected in Spain [25], the United Kingdom (UK) [13], Italy [16,45], Germany, France [77] and Portugal [78,79]. In Albania [80], Hungary [81] and Turkey [82], CPV-2a and mutants are widely spread. In Australia, New Zealand, and Oceania, investigation of CPV in dogs has demonstrated that CPV-2a remains the predominant genetic variant, and has not been replaced by CPV-2b or CPV-2c, as in many other countries [83,84]. In Africa, infection of dogs with either CPV-2a or -2b was




Fig 3. (A) Distribution of cumulative numbers of CPV case reports, and (B) the percentages of canine parvovirus variants, categorized by continent. Bar graphs are constructed from the available recent public data to mid-2016

reported in Nigeria, Mozambique, and South Africa [85,86]; however, the CPV-2c strain was found to be present in Morocco [87]. The numbers and percentages of detected CPV cases are summarized by region in Fig. 3.

### DIAGNOSTIC TOOLS FOR CPV ANTIGEN AND ANTIBODY DETECTION

Canine parvovirus infection is the main viral etiology responsible for diarrhea in dogs. This disease may be differentially diagnosed by the time of clinical manifestation. Some viruses, such as morbillivirus, rotavirus, coronavirus, adenoviruses, reovirus, and norovirus, have contributed to causing diarrhea in dogs [2]. The virus causing gastroenteritis should be confirmed by laboratory diagnosis in order to be distinguished from bacterial enteritis. CPV infection causing gastroenteritis is usually a major cause of illness in the early life of dogs. The feces, intestinal contents, or tissues from affected dogs, or even EDTA blood samples at the time of viremia, have proven to be useful in diagnosis [25,43,88].

In recent years, many research groups have attempted to validate the use of various methods to detect the presence of CPV as a causative virus. Some are working on antibody-based tests for rapid detection of CPV antigens. Several studies have demonstrated that ELISA test kits are able to detect CPV antigens and have shown promising sensitivity and specificity toward new variants of CPV [89,90]. A recent study compared commercial antibody-based tests for rapid detection of CPV antigens with other detection methods, i.e. PCR and immunoelectron microscopy (IEM). The results revealed the high specificity and low sensitivity of the antigen-detection kits [91].

Molecular biology techniques, such as traditional polymerase chain reaction (PCR) and quantitative PCR (real-time PCR; qPCR) have been widely developed and used in the detection of CPV genetic materials from blood and fecal samples [7,41,43,48]. Because of the sensitivity, specificity, and reproducibility of PCR and real-time PCR in detection of CPV DNA, this method might replace traditional methods such as virus isolation and antibody detection. Real-time PCR technology, using SYBR Green or minor groove binding (MGB) TaqMan probes for PCR assays, has many

advantages over conventional PCR [6,7,92]. The quantification of virus load is one example of the many applications for exploiting qPCR. Real-time PCR can also be performed with a large throughput to achieve an inexpensive and time-saving method [41].

As documented in Desario et al. [43], monoclonal anti-bodies (mAbs) can be raised against CPV-2 types in order to determine the hemagglutination inhibition (HI) titers in different viral variants. Abs clones A4E3, B4A2, C1D1, and B4E1 were unequally recognized major epitopes in original CPV type 2, CPV-2a, CPV-2b, and CPV-2c (formerly known as Glu-426 mutant) [43]. The clones A4E3 and C1D1 demonstrated superior reactivity with nearly all CPV variants [43]. The change in CPV-2c at amino acid residue 426 has shown differences in antigenic determination by the monoclonal antibodies 21C3 and 19D7 [6,42].

## CANINE PARVOVIRUS VACCINES: FUTURE PERSPECTIVES

The original CPV-2-based vaccines have been proven to provide secure immunization against CPV-2c in Italian isolates [1]. The antibodies produced in dogs vaccinated with the latest CPV-2b field strain have shown more promising reactivity than the traditional CPV-2 strain vaccines [59]. The observed antigenic contrasts may drive the selection of CPV strains by producing differential immunogenic pressures among canine populations, which raises concerns about immunization efficiency [44]. The CPV-2c variation displayed a one-of-a-kind antigenic example, since it was inadequately recognized by specific antibodies of dogs inoculated with CPV-2, CPV-2a, and CPV-2b strains [44]. Several studies have demonstrated that CPV-2 vaccines can be used to promote CPV-2 antibodies against CPV variants [93-96]. A new modified live CPV vaccine (CPV-MLV) recently launched in the marketplace is designed from the CPV-2b variant, or can be genetically engineered to simulate the new CPV-2c variant [44,93]. In the serum neutralization (SN) test, titers to the antigenic variants CPV-2a, CPV-2b, and CPV-2c in immunized dogs were significantly lower than the homologous titers (raised to the original type) [11,44,95]. As previously observed by Pratelli et al. [95], the greatest antigenic differences were found in comparison with the original CPV-2, which is still largely utilized in vaccine manufacturing [44]. The SN immunologic method has been found to provide greater clarity and contrast than HI in cross-antigenic assessment of CPV-2 variability. The heterologous SN titers (versus CPV-2a and -2c) were significantly lower than the homologous SN titer (versus CPV-2b) [44]. After inoculation with the CPV-2c variant, lower SN titer was found in the sera of dogs and rabbits immunized with heterologous (CPV-2, -2a, and -2b) viruses. Moreover, these discoveries suggest the opportunity to develop modified live virus (MLV) vaccines from the CPV-2c strain [44]. Another study

has also confirmed the notion that the current vaccine regimen, made from nucleotide sequences of CPV-2b, can provide antigenic cross-protection of dogs from the CPV-2c variant [97]. In the case of maternal antibodies, a specific titer might provide adequate resistance to disease caused by homologous CPV infection, but it may not fully protect puppies if they encounter a heterologous virus strain [11].

## CONCLUSIONS

The continuous antigenic evolution of CPV-2 has caused the rapid displacement of older strains by a new antigenic variant strain, CPV-2c, which emerged in Italy in early 2000 [78] is spreading with high morbidity and mortality in the dog populations of Italy and neighboring countries. This progressive mutant is now replacing the antigenic variants CPV-2a and -2b [15]. Studies by authors from many countries, i.e., Italy, Portugal, Spain, France, United Kingdom, Belgium, Germany, Greece, Bulgaria, Tunisia, United States, Uruguay, Argentina, China, Taiwan, Vietnam, Thailand, Laos, and India, have demonstrated that the new variant 2c is a global threat for puppies. The substitution of CPV-2 by strains -2a and -2b, and then -2c, has been connected with expanded receptor-binding capacity to canine transferrin receptors. The mutation at Glu-426 confers the benefit of infectivity and, even more, influences clinical disease status. Continuing progress in vaccine development will determine whether the CPV vaccines currently in use will still provide full protection against the new variant or whether we should be prepared to replace those homologous vaccines with a novel technology, heterologous vaccines.

## CONFLICT OF INTEREST

The authors declare that they have no conflict of interest regarding the publication of this paper.

## ACKNOWLEDGEMENTS

This work was supported by an internal fund for graduate research from the Faculty of Veterinary Medicine, Chiang Mai University. The authors are also grateful for research funding from the Excellent Center in Veterinary Bioscience, Chiang Mai University, Chiang Mai, Thailand. We are also very grateful for an Asian Development Bank Scholarship (ADB) Project No. 43120-013: LAO-Trade Facilitation: Improved Sanitary and Phytosanitary (SPS) Handling in Greater Mekong Subregion (GMS) Trade Project.

## REFERENCES

1. Kapil S, Cooper E, Lamm C, Murray B, Rezabek G, Johnston L, Campbell G, Johnson B: Canine parvovirus types 2c and 2b circulating in North American dogs in 2006 and 2007. *J Clin Microbiol*, 45, 4044-4047, 2007. DOI: 10.1128/JCM.01300-07

- 2. Greene CE, Decaro N:** Canine viral enteritis. In, Greene CE (Ed): Infectious diseases of the dog and cat. 4<sup>th</sup> edn., 67-80, Elsevier/Saunders, St. Louis, MO, 2012.
- 3. Berns K, Parrish CR:** Parvoviridae. In, Knipe DM, Howley PM (Eds): Fields' Virology. 5<sup>th</sup> edn., 2437-2478, Lippincott, Williams & Wilkins, Philadelphia, PA, 2007.
- 4. Elia G, Cavalli A, Cirone F, Lorusso E, Camero M, Buonavoglia D, Tempesta M:** Antibody levels and protection to canine parvovirus type 2. *Zoonoses Public Health*, 52, 320-322, 2005. DOI: 10.1111/j.1439-0450.2005.00870.x
- 5. Decaro N, Martella V, Elia G, Desario C, Campolo M, Lorusso E, Colaiani ML, Lorusso A, Buonavoglia C:** Tissue distribution of the antigenic variants of canine parvovirus type 2 in dogs. *Vet Microbiol*, 121, 39-44, 2007. DOI: 10.1016/j.vetmic.2006.11.005
- 6. Hong C, Decaro N, Desario C, Tanner P, Pardo MC, Sanchez S, Buonavoglia C, Saliki JT:** Occurrence of canine parvovirus type 2c in the United States. *J Vet Diagn Invest*, 19, 535-539, 2007. DOI: 10.1177/104063870701900512
- 7. Lin C-N, Chien C-H, Chiou M-T, Wang J-W, Lin Y-L, Xu Y-M:** Development of SYBR green-based real-time PCR for the detection of canine, feline and porcine parvoviruses. *Taiwan Vet J*, 40, 1-9, 2014. DOI: 10.1142/S1682648514500012
- 8. Cotmore SF, Agbandje-McKenna M, Chiorini JA, Mukha DV, Pintel DJ, Qiu J, Soderlund-Venermo M, Tattersall P, Tijssen P, Gatherer D:** The family Parvoviridae. *Arch Virol*, 159, 1239-1247, 2014. DOI: 10.1007/s00705-013-1914-1
- 9. Xu J, Guo HC, Wei YQ, Shu L, Wang J, Li JS, Cao SZ, Sun SQ:** Phylogenetic analysis of canine parvovirus isolates from Sichuan and Gansu provinces of China in 2011. *Transbound Emerg Dis*, 62, 91-95, 2015. DOI: 10.1111/tbed.12078
- 10. Wu H, Rossmann MG:** The canine parvovirus empty capsid structure. *J Mol Biol*, 233, 231-244, 1993. DOI: 10.1006/jmbi.1993.1502
- 11. Truyen U:** Evolution of canine parvovirus - a need for new vaccines? *Vet Microbiol*, 117, 9-13, 2006. DOI: 10.1016/j.vetmic.2006.04.003
- 12. Appel M, Scott F, Carmichael L:** Isolation and immunisation studies of a canine parvo-like virus from dogs with haemorrhagic enteritis. *Vet Rec*, 105, 156-159, 1979. DOI: 10.1136/vr.105.8.156
- 13. Clegg S, Coyne K, Parker J, Dawson S, Godsall S, Pinchbeck G, Cripps P, Gaskell R, Radford A:** Molecular epidemiology and phylogeny reveal complex spatial dynamics in areas where canine parvovirus is endemic. *J Virol*, 85, 7892-7899, 2011. DOI: 10.1128/JVI.01576-10
- 14. Filipov C, Decaro N, Desario C, Amorisco F, Sciarretta R, Buonavoglia C:** Canine parvovirus epidemiology in Bulgaria. *J Vet Diagn Invest*, 23, 152-154, 2011. DOI: 10.1177/104063871102300129
- 15. Ntafis V, Xylouri E, Kalli I, Desario C, Mari V, Decaro N, Buonavoglia C:** Characterization of Canine parvovirus 2 variants circulating in Greece. *J Vet Diagn Invest*, 22, 737-740, 2010. DOI: 10.1177/104063871002200512
- 16. Buonavoglia C, Martella V, Pratelli A, Tempesta M, Cavalli A, Buonavoglia D, Bozzo G, Elia G, Decaro N, Carmichael L:** Evidence for evolution of canine parvovirus type 2 in Italy. *J Gen Virol*, 82, 3021-3025, 2001. DOI: 10.1099/0022-1317-82-12-3021
- 17. Calderon MG, Mattion N, Bucafusco D, Fogel F, Remorini P, La Torre J:** Molecular characterization of canine parvovirus strains in Argentina: detection of the pathogenic variant CPV2c in vaccinated dogs. *J Virol Methods*, 159, 141-145, 2009. DOI: 10.1016/j.jviromet.2009.03.013
- 18. Pérez R, Francia L, Romero V, Maya L, López I, Hernández M:** First detection of canine parvovirus type 2c in South America. *Vet Microbiol*, 124, 147-152, 2007. DOI: 10.1016/j.vetmic.2007.04.028
- 19. Castro T, Costa E, Leite J, Labarthe N, Garcia RC:** Monitoring of canine parvovirus (CPV) strains detected in vaccinated puppies in Brazil. *Res Vet Sci*, 90, 336-340, 2011. DOI: 10.1016/j.rvsc.2010.06.005
- 20. Monteiro K, Allendorf SD, Vicente AF, Appolinário CM, Peres MG, Cortez A, Heinemann MB, Megid J:** Viral type characterization and clinical aspects of canine parvovirus in naturally infected dogs in São Paulo State, Brazil. *Pesqui Vet Bras*, 36, 1181-1185, 2016. DOI: 10.1590/s0100-736x2016001200007
- 21. Mukhopadhyay H, Matta SL, Amsaveni S, Antony P, Thanisslass J, Pillai R:** Phylogenetic analysis of canine parvovirus partial VP2 gene in India. *Virus Genes*, 48, 89-95, 2014. DOI: 10.1007/s11262-013-1000-5
- 22. Nandi S, Chidri S, Kumar M, Chauhan R:** Occurrence of canine parvovirus type 2c in the dogs with haemorrhagic enteritis in India. *Res Vet Sci*, 88, 169-171, 2010. DOI: 10.1016/j.rvsc.2009.05.018
- 23. Shackelton LA, Parrish CR, Truyen U, Holmes EC:** High rate of viral evolution associated with the emergence of carnivore parvovirus. *Proc Natl Acad Sci U S A*, 102, 379-384, 2005. DOI: 10.1073/pnas.0406765102
- 24. Hueffer K, Parker JS, Weichert WS, Geisel RE, Sgro J-Y, Parrish CR:** The natural host range shift and subsequent evolution of canine parvovirus resulted from virus-specific binding to the canine transferrin receptor. *J Virol*, 77, 1718-1726, 2003. DOI: 10.1128/JVI.77.3.1718-1726.2003
- 25. Decaro N, Martella V, Desario C, Bellacicco A, Camero M, Manna L, d'Aloja D, Buonavoglia C:** First detection of canine parvovirus type 2c in pups with haemorrhagic enteritis in Spain. *J Vet Med B Infect Dis Vet Public Health*, 53, 468-472, 2006. DOI: 10.1111/j.1439-0450.2006.00974.x
- 26. Phromnoi S, Sirinarumitr K, Sirinarumitr T:** Sequence analysis of VP2 gene of canine parvovirus isolates in Thailand. *Virus Genes*, 41, 23-29, 2010. DOI: 10.1007/s11262-010-0475-6
- 27. Organtini LJ, Allison AB, Lukk T, Parrish CR, Hafenstein S:** Global displacement of canine parvovirus by a host-adapted variant: Structural comparison between pandemic viruses with distinct host ranges. *J Virol*, 89, 1909-1912, 2015. DOI: 10.1128/JVI.02611-14
- 28. Miranda C, Thompson G:** Canine parvovirus: The worldwide occurrence of antigenic variants. *J Gen Virol*, 97, 2043-2057, 2016. DOI: 10.1099/jgv.0.000540
- 29. Callaway HM, Feng KH, Lee DW, Allison AB, Pinard M, McKenna R, Agbandje-McKenna M, Hafenstein S, Parrish CR:** Parvovirus capsid structures required for infection: Mutations controlling receptor recognition and protease cleavages. *J Virol*, 91, e01871-01816, 2017. DOI: 10.1128/JVI.01871-16
- 30. Cureton DK, Harbison CE, Cocucci E, Parrish CR, Kirchhausen T:** Limited transferrin receptor clustering allows rapid diffusion of canine parvovirus into clathrin endocytic structures. *J Virol*, 86, 5330-5340, 2012. DOI: 10.1128/JVI.07194-11
- 31. Hafenstein S, Palermo LM, Kostyuchenko VA, Xiao C, Morais MC, Nelson CD, Bowman VD, Battisti AJ, Chipman PR, Parrish CR:** Asymmetric binding of transferrin receptor to parvovirus capsids. *Proc Natl Acad Sci USA*, 104, 6585-6589, 2007. DOI: 10.1073/pnas.0701574104
- 32. Allison AB, Organtini LJ, Zhang S, Hafenstein SL, Holmes EC, Parrish CR:** Single mutations in the VP2 300 loop region of the three-fold spike of the carnivore parvovirus capsid can determine host range. *J Virol*, 90, 753-767, 2016. DOI: 10.1128/JVI.02636-15
- 33. Tzeng SR, Kalodimos CG:** Dynamic activation of an allosteric regulatory protein. *Nature*, 462, 368-372, 2009. DOI: 10.1038/nature08560
- 34. Parker J, Parrish CR:** Canine parvovirus host range is determined by the specific conformation of an additional region of the capsid. *J Virol*, 71, 9214-9222, 1997.
- 35. Palermo LM, Hafenstein SL, Parrish CR:** Purified feline and canine transferrin receptors reveal complex interactions with the capsids of canine and feline parvoviruses that correspond to their host ranges. *J Virol*, 80, 8482-8492, 2006. DOI: 10.1128/JVI.00683-06
- 36. Goodman LB, Lyi SM, Johnson NC, Cifuentes JO, Hafenstein SL, Parrish CR:** Binding site on the transferrin receptor for the parvovirus capsid and effects of altered affinity on cell uptake and infection. *J Virol*, 84, 4969-4978, 2010. DOI: 10.1128/JVI.02623-09
- 37. Kaelber JT, Demogines A, Harbison CE, Allison AB, Goodman LB, Ortega AN, Sawyer SL, Parrish CR:** Evolutionary reconstructions of the transferrin receptor of caniforms supports canine parvovirus being a reemerged and not a novel pathogen in dogs. *PLoS Pathog.*, 8, e1002666, 2012. DOI: 10.1371/journal.ppat.1002666
- 38. Allison AB, Kohler DJ, Ortega A, Hoover EA, Grove DM, Holmes EC, Parrish CR:** Host-specific parvovirus evolution in nature is recapitulated by *in vitro* adaptation to different carnivore species. *PLoS Pathog.*, 10,



e1004475, 2014. DOI: 10.1371/journal.ppat.1004475

- 39. Parker JS, Murphy WJ, Wang D, O'Brien SJ, Parrish CR:** Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. *J Virol*, 75, 3896-3902, 2001. DOI: 10.1128/JVI.75.8.3896-3902.2001
- 40. Govindasamy L, Hueffer K, Parrish CR, Agbandje-McKenna M:** Structures of host range-controlling regions of the capsids of canine and feline parvoviruses and mutants. *J Virol*, 77, 12211-12221, 2003. DOI: 10.1128/JVI.77.22.12211-12221.2003
- 41. Decaro N, Desario C, Campolo M, Elia G, Martella V, Ricci D, Lorusso E, Buonavoglia C:** Clinical and virological findings in pups naturally infected by canine parvovirus type 2 Glu-426 mutant. *J Vet Diagn Invest*, 17, 133-138, 2005. DOI: 10.1177/104063870501700206
- 42. Nakamura M, Tohya Y, Miyazawa T, Mochizuki M, Phung H, Nguyen N, Huynh L, Nguyen L, Nguyen P, Nguyen P:** A novel antigenic variant of canine parvovirus from a Vietnamese dog. *Arch Virol*, 149, 2261-2269, 2004. DOI: 10.1007/s00705-004-0367-y
- 43. Desario C, Decaro N, Campolo M, Cavalli A, Cirone F, Elia G, Martella V, Lorusso E, Camero M, Buonavoglia C:** Canine parvovirus infection: which diagnostic test for virus? *J Virol Methods*, 126, 179-185, 2005. DOI: 10.1016/j.jviromet.2005.02.006
- 44. Cavalli A, Martella V, Desario C, Camero M, Bellacicco AL, De Palo P, Decaro N, Elia G, Buonavoglia C:** Evaluation of the antigenic relationships among canine parvovirus type 2 variants. *Clin Vaccine Immunol*, 15, 534-539, 2008. DOI: 10.1128/CVI.00444-07
- 45. Decaro N, Desario C, Parisi A, Martella V, Lorusso A, Miccolupo A, Mari V, Colaianni ML, Cavalli A, Di Trani L:** Genetic analysis of canine parvovirus type 2c. *Virology*, 385, 5-10, 2009. DOI: 10.1016/j.virol.2008.12.016
- 46. Lin CN, Chien CH, Chiou MT, Chueh LL, Hung MY, Hsu HS:** Genetic characterization of type 2a canine parvoviruses from Taiwan reveals the emergence of an Ile324 mutation in VP2. *Virol J*, 11, 1, 2014. DOI: 10.1186/1743-422X-11-39
- 47. Wang H, Jin H, Li Q, Zhao G, Cheng N, Feng N, Zheng X, Wang J, Zhao Y, Li L:** Isolation and sequence analysis of the complete NS1 and VP2 genes of canine parvovirus from domestic dogs in 2013 and 2014 in China. *Arch Virol*, 161, 385-393, 2016. DOI: 10.1007/s00705-015-2620-y
- 48. Decaro N, Elia G, Desario C, Roperto S, Martella V, Campolo M, Lorusso A, Cavalli A, Buonavoglia C:** A minor groove binder probe real-time PCR assay for discrimination between type 2-based vaccines and field strains of canine parvovirus. *J Virol Methods*, 136, 65-70, 2006. DOI: 10.1016/j.jviromet.2006.03.030
- 49. Kang B-K, Song D-S, Lee C-S, Jung K-I, Park S-J, Kim E-M, Park B-K:** Prevalence and genetic characterization of canine parvoviruses in Korea. *Virus Genes*, 36, 127-133, 2008. DOI: 10.1007/s11262-007-0189-6
- 50. Calderón MG, Romanutti C, D'Antuono A, Keller L, Mattion N, La Torre J:** Evolution of canine parvovirus in Argentina between years 2003 and 2010: CPV2c has become the predominant variant affecting the domestic dog population. *Virus Res*, 157, 106-110, 2011. DOI: 10.1016/j.virusres.2011.02.015
- 51. Calderón MG, Romanutti C, Wilda M, D'Antuono A, Keller L, Giacomodonato MN, Mattion N, La Torre J:** Resurgence of canine parvovirus 2a strain in the domestic dog population from Argentina. *J Virol Methods*, 222, 145-149, 2015. DOI: 10.1016/j.jviromet.2015.06.012
- 52. Aldaz J, García-Díaz J, Calleros L, Sosa K, Iraola G, Marandino A, Hernández M, Panzera Y, Pérez R:** High local genetic diversity of canine parvovirus from Ecuador. *Vet Microbiol*, 166, 214-219, 2013. DOI: 10.1016/j.vetmic.2013.06.012
- 53. Pérez R, Bianchi P, Calleros L, Francia L, Hernández M, Maya L, Panzera Y, Sosa K, Zoller S:** Recent spreading of a divergent canine parvovirus type 2a (CPV-2a) strain in a CPV-2c homogenous population. *Vet Microbiol*, 155, 214-219, 2012. DOI: 10.1016/j.vetmic.2011.09.017
- 54. Costa A, Leite JPG, Labarthe N, Garcia RC:** Genomic typing of canine parvovirus circulating in the State of Rio de Janeiro, Brazil from 1995 to 2001 using polymerase chain reaction assay. *Vet Res Commun*, 29, 735-743, 2005. DOI: 10.1007/s11259-005-3865-9
- 55. Duque-García Y, Echeverri-Zuluaga M, Trejos-Suarez J, Ruiz-Saenz J:** Prevalence and molecular epidemiology of Canine parvovirus 2 in diarrheic dogs in Colombia, South America: A possible new CPV-2a is emerging? *Vet Microbiol*, 201, 56-61, 2017. DOI: 10.1016/j.vetmic.2016.12.039
- 56. Markovich JE, Stucker KM, Carr AH, Harbison CE, Scarlett JM, Parrish CR:** Effects of canine parvovirus strain variations on diagnostic test results and clinical management of enteritis in dogs. *J Am Vet Med Assoc*, 241, 66-72, 2012. DOI: 10.2460/javma.241.1.66
- 57. Pedroza-Roldán C, Páez-Magallan V, Charles-Niño C, Elizondo-Quiroga D, Leonel De Cervantes-Mireles R, López-Amezcu MA:** Genotyping of Canine parvovirus in western Mexico. *J Vet Diagn Invest*, 27, 107-111, 2015. DOI: 10.1177/1040638714559969
- 58. Gagnon CA, Allard V, Cloutier G:** Canine parvovirus type 2b is the most prevalent genomic variant strain found in parvovirus antigen positive diarrheic dog feces samples across Canada. *Can Vet J*, 57, 29, 2016.
- 59. Ohshima T, Hisaka M, Kawakami K, Kishi M, Tohya Y, Mochizuki M:** Chronological analysis of canine parvovirus type 2 isolates in Japan. *J Vet Med Sci*, 70, 769-775, 2008. DOI: 10.1292/jvms.70.769
- 60. Soma T, Taharaguchi S, Ohinata T, Ishii H, Hara M:** Analysis of the VP2 protein gene of canine parvovirus strains from affected dogs in Japan. *Res Vet Sci*, 94, 368-371, 2013. DOI: 10.1016/j.rvsc.2012.09.013
- 61. Chou SJ, Lin HT, Wu JT, Yang WC, Chan KW:** Genotyping of canine parvovirus type 2 VP2 gene in southern Taiwan in 2011. *Taiwan Vet J*, 39, 81-92, 2013.
- 62. Jeoung S-, Ahn SJ, Kim D:** Genetic analysis of VP2 gene of canine parvovirus isolates in Korea. *J Vet Med Sci*, 70, 719-722, 2008. DOI: 10.1292/jvms.70.719
- 63. Yoon SH, Jeong W, Kim H-J, An D-J:** Molecular insights into the phylogeny of canine parvovirus 2 (CPV-2) with emphasis on Korean isolates: A Bayesian approach. *Arch Virol*, 154, 1353-1360, 2009. DOI: 10.1007/s00705-009-0444-3
- 64. Vannamahaxay S, Vongkhamchanh S, Intanon M, Tangtrongsup S, Tiwananthagorn S, Pringproa K, Chuammitri P:** Molecular characterization of canine parvovirus in Vientiane, Laos. *Arch Virol*, 162, 1355-1361, 2017. DOI: 10.1007/s00705-016-3212-1
- 65. Chiang SY, Wu HY, Chiou MT, Chang MC, Lin CN:** Identification of a novel canine parvovirus type 2c in Taiwan. *Virol J*, 13, 160, 2016. DOI: 10.1186/s12985-016-0620-5
- 66. Wu J, Gao XT, Hou SH, Guo XY, Yang XS, Yuan WF, Xin T, Zhu HF, Jia H:** Molecular epidemiological and phylogenetic analyses of canine parvovirus in domestic dogs and cats in Beijing, 2010-2013. *J Vet Med Sci*, 77, 1305-1310, 2015. DOI: 10.1292/jvms.14-0665
- 67. Yi L, Tong M, Cheng Y, Song W, Cheng S:** Phylogenetic analysis of canine parvovirus VP2 gene in China. *Transbound Emerg Dis*, 63, e262-e269, 2016. DOI: 10.1111/tbed.12268
- 68. Zhou L, Tang Q, Shi L, Kong M, Liang L, Mao Q, Bu B, Yao L, Zhao K, Cui S:** Full-length genomic characterization and molecular evolution of canine parvovirus in China. *Virus Genes*, 52, 411-416, 2016. DOI: 10.1007/s11262-016-1309-y
- 69. Wang J, Lin P, Zhao H, Cheng Y, Jiang Z, Zhu H, Wu H, Cheng S:** Continuing evolution of canine parvovirus in China: Isolation of novel variants with an Ala5Gly mutation in the VP2 protein. *Infect Genet Evol*, 38, 73-78, 2016. DOI: 10.1016/j.meegid.2015.12.009
- 70. Zhao H, Wang J, Jiang Y, Cheng Y, Lin P, Zhu H, Han G, Yi L, Zhang S, Guo L:** Typing of Canine Parvovirus Strains Circulating in North-East China. *Transbound Emerg Dis*, 2015. DOI: 10.1111/tbed.12390
- 71. Zhong Z, Liang L, Zhao J, Xu X, Cao X, Liu X, Zhou Z, Ren Z, Shen L, Geng Y:** First isolation of new canine parvovirus 2a from Tibetan mastiff and global analysis of the full-length VP2 gene of canine parvoviruses 2 in China. *Int J Mol Sci*, 15, 12166-12187, 2014. DOI: 10.3390/ijms150712166
- 72. Mittal M, Chakravarti S, Mohapatra J, Chug P, Dubey R, Upmanuy V, Narwal P, Kumar A, Churamani C, Kanwar N:** Molecular typing of canine parvovirus strains circulating from 2008 to 2012 in an organized kennel in India reveals the possibility of vaccination failure. *Infect Genet Evol*, 23, 1-6, 2014. DOI: 10.1016/j.meegid.2014.01.015

- 73. Dastmalchi Saei H, Javadi S, Akbari S, Hadian N, Zarza E:** Molecular characterization of canine parvovirus (CPV) antigenic variants from healthy and diarrheic dogs in Urmia region, Iran. *Iran J Vet Med*, 11, 9-19, 2017.
- 74. Kaur G, Chandra M, Dwivedi P, Narang D:** Multiplex real-time PCR for identification of canine parvovirus antigenic types. *J Virol Methods*, 233, 1-5, 2016. DOI: 10.1016/j.jviromet.2016.02.013
- 75. Nookala M, Mukhopadhyay HK, Sivaprakasam A, Balasubramanian B, Antony PX, Thanislass J, Srinivas MV, Pillai RM:** Full-length VP2 gene analysis of canine parvovirus reveals emergence of newer variants in India. *Acta Microbiol Immunol Hung*, 63, 411-426, 2016. DOI: 10.1556/030.63.2016.010
- 76. Decaro N, Desario C, Addie DD, Martella V, Vieira MJ, Elia G, Zicola A, Davis C, Thompson G, Thiry E:** Molecular epidemiology of canine parvovirus, Europe. *Emerg Infect Dis*, 13, 1222, 2007. DOI: 10.3201/eid1308.070505
- 77. Decaro N, Desario C, Amorisco F, Losurdo M, Elia G, Parisi A, Ventrella G, Martella V, Buonavoglia C:** Detection of a canine parvovirus type 2c with a non-coding mutation and its implications for molecular characterisation. *Vet J*, 196, 555-557, 2013. DOI: 10.1016/j.tvjl.2012.12.017
- 78. Vieira MJ, Silva E, Oliveira J, Vieira AL, Decaro N, Desario C, Muller A, Carvalheira J, Buonavoglia C, Thompson G:** Canine parvovirus 2c infection in central Portugal. *J Vet Diagn Invest*, 20, 488-491, 2008. DOI: 10.1177/104063870802000412
- 79. Miranda C, Parrish CR, Thompson G:** Epidemiological evolution of canine parvovirus in the Portuguese domestic dog population. *Vet Microbiol*, 183, 37-42, 2016. DOI: 10.1016/j.vetmic.2015.11.037
- 80. Cavalli A, Desario C, Kusi I, Mari V, Lorusso E, Cirone F, Kumbe I, Colaiani ML, Buonavoglia D, Decaro N:** Detection and genetic characterization of Canine parvovirus and Canine coronavirus strains circulating in district of Tirana in Albania. *J Vet Diagn Invest*, 26, 563-566, 2014. DOI: 10.1177/1040638714538965
- 81. Cságola A, Varga S, Lőrincz M, Tuboly T:** Analysis of the full-length VP2 protein of canine parvoviruses circulating in Hungary. *Arch Virol*, 159, 2441-2444, 2014. DOI: 10.1007/s00705-014-2068-5
- 82. Timurkan M, Oğuzoğlu T:** Molecular characterization of canine parvovirus (CPV) infection in dogs in Turkey. *Vet Ital*, 51, 39-44, 2015. DOI: 10.12834/VetIt.263.908.3
- 83. Meers J, Kyaw-Tanner M, Bensink Z, Zwijnenberg R:** Genetic analysis of canine parvovirus from dogs in Australia. *Aust Vet J*, 85, 392-396, 2007. DOI: 10.1111/j.1751-0813.2007.00206.x
- 84. Ohneiser S, Hills S, Cave N, Passmore D, Dunowska M:** Canine parvoviruses in New Zealand form a monophyletic group distinct from the viruses circulating in other parts of the world. *Vet Microbiol*, 178, 190-200, 2015. DOI: 10.1016/j.vetmic.2015.05.017
- 85. Dogonyaro BB, Bosman A-M, Sibeko KP, Venter EH, van Vuuren M:** Genetic analysis of the VP2-encoding gene of canine parvovirus strains from Africa. *Vet Microbiol*, 165, 460-465, 2013. DOI: 10.1016/j.vetmic.2013.04.022
- 86. Figueiredo J, Miranda C, Souto R, Silva E, Fafetine J, Thompson G:** Genetic characterization of canine parvovirus type 2 subtypes in Maputo, Mozambique. *Arch Microbiol*, 1-7, 2016. DOI: 10.1007/s00203-016-1320-7
- 87. Amrani N, Desario C, Kadiri A, Cavalli A, Berrada J, Zro K, Sebbar G, Colaiani ML, Parisi A, Elia G:** Molecular epidemiology of canine parvovirus in Morocco. *Infect Genet Evol*, 41, 201-206, 2016. DOI: 10.1016/j.meegid.2016.04.005
- 88. Decaro N, Desario C, Billi M, Mari V, Elia G, Cavalli A, Martella V, Buonavoglia C:** Western European epidemiological survey for parvovirus and coronavirus infections in dogs. *Vet J*, 187, 195-199, 2011. DOI: 10.1016/j.tvjl.2009.10.027
- 89. Decaro N, Desario C, Beall MJ, Cavalli A, Campolo M, DiMarco AA, Amorisco F, Colaiani ML, Buonavoglia C:** Detection of canine parvovirus type 2c by a commercially available in-house rapid test. *Vet J*, 184, 373-375, 2010. DOI: 10.1016/j.tvjl.2009.04.006
- 90. Kantere MC, Athanasiou LV, Spyrou V, Kyriakis CS, Kontos V, Chatzopoulos DC, Tsokana CN, Billinis C:** Diagnostic performance of a rapid in-clinic test for the detection of Canine Parvovirus under different storage conditions and vaccination status. *J Virol Methods*, 215, 52-55, 2015. DOI: 10.1016/j.jviromet.2015.02.012
- 91. Schmitz S, Coenen C, Matthias K, Heinz-Jürgen T, Neiger R:** Comparison of three rapid commercial canine parvovirus antigen detection tests with electron microscopy and polymerase chain reaction. *J Vet Diagn Invest*, 21, 344-345, 2009. DOI: 10.1177/104063870902100306
- 92. Decaro N, Martella V, Elia G, Desario C, Campolo M, Buonavoglia D, Bellacicco AL, Tempesta M, Buonavoglia C:** Diagnostic tools based on minor groove binder probe technology for rapid identification of vaccinal and field strains of canine parvovirus type 2b. *J Virol Methods*, 138, 10-16, 2006. DOI: 10.1016/j.jviromet.2006.07.011
- 93. Kapil S, Cooper E:** Vaccines containing canine parvovirus genetic variants. U.S. Patent No. 8,258,274. 4 Sep. 2012.
- 94. Patial S, Chaturvedi V, Rai A, Saini M, Chandra R, Saini Y, Gupta PK:** Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2. *Vaccine*, 25, 4020-4028, 2007. DOI: 10.1016/j.vaccine.2007.02.051
- 95. Pratelli A, Cavalli A, Martella V, Tempesta M, Decaro N, Carmichael LE, Buonavoglia C:** Canine parvovirus (CPV) vaccination: Comparison of neutralizing antibody responses in pups after inoculation with CPV2 or CPV2b modified live virus vaccine. *Clin Diagn Lab Immunol*, 8, 612-615, 2001. DOI: 10.1128/CDLI.8.3.612-615.2001
- 96. Yule TD, Roth MB, Dreier K, Johnson AF, Palmer-Densmore M, Simmons K, Fanton R:** Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease. *Vaccine*, 15, 720-729, 1997. DOI: 10.1016/S0264-410X(96)00232-0
- 97. Spibey N, Greenwood N, Sutton D, Chalmers W, Tarpey I:** Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. *Vet Microbiol*, 128, 48-55, 2008. DOI: 10.1016/j.vetmic.2007.09.015